1-(2,6-dichlorophenyl)indolin-2-one is a chemical compound with the molecular formula C14H9Cl2NO. It is a derivative of indoline-2-one, which is a cyclic amide with a six-membered ring containing nitrogen.
**Importance for Research:**
1-(2,6-dichlorophenyl)indolin-2-one has garnered attention in research due to its potential pharmacological properties. Here's why:
* **Antioxidant Activity:** Studies have shown that this compound exhibits significant antioxidant activity. This means it can neutralize free radicals, which are harmful molecules that contribute to cellular damage and various diseases.
* **Anti-inflammatory Properties:** Some research suggests that 1-(2,6-dichlorophenyl)indolin-2-one possesses anti-inflammatory properties. This makes it potentially useful in treating inflammatory conditions like arthritis.
* **Antibacterial Activity:** Research indicates that this compound might have antibacterial activity. It could be explored as a potential alternative to conventional antibiotics.
* **Anti-cancer Potential:** Preliminary studies suggest that 1-(2,6-dichlorophenyl)indolin-2-one may have anti-cancer properties. This is a promising area of ongoing investigation.
* **Other Potential Applications:** The compound's unique structure and pharmacological profile make it a candidate for further research into other therapeutic applications, such as treatment of Alzheimer's disease and Parkinson's disease.
**Important Note:**
While research shows promise, it's crucial to understand that these are still early findings. More research is necessary to fully understand the mechanisms of action, efficacy, and safety of 1-(2,6-dichlorophenyl)indolin-2-one in humans.
**Conclusion:**
1-(2,6-dichlorophenyl)indolin-2-one is a compound with potential therapeutic properties due to its antioxidant, anti-inflammatory, and antibacterial activities. Ongoing research is exploring its potential applications in medicine, making it an important subject for scientists.
1-(2,6-dichlorophenyl)indolin-2-one: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 27211 |
| CHEMBL ID | 487716 |
| SCHEMBL ID | 2982634 |
| MeSH ID | M0427489 |
| Synonym |
|---|
| HMS1479O03 |
| AC-327 |
| MLS000527383 |
| 1-(2,6-dichlorophenyl)-2-indolinone |
| smr000117857 |
| UPCMLD0ENAT5559022:001 |
| nsc621845 |
| nsc-621845 |
| 1-(2,6-dichloro-phenyl)-1,3-dihydro-indol-2-one |
| NCI60_006351 |
| 1-(2,6-dichlorophenyl)indolin-2-one |
| 1-(2,6-dichlorophenyl)-1,3-dihydro-2h-indol-2-one |
| einecs 239-399-3 |
| 2h-indol-2-one, 1,3-dihydro-1-(2,6-dichlorophenyl)- |
| brn 1538309 |
| 1,3-dihydro-1-(2,6-dichlorophenyl)-2h-indol-2-one |
| CHEMDIV3_002423 , |
| AKOS000530778 |
| 15362-40-0 |
| BRD-K18569286-001-01-2 |
| CHEMBL487716 |
| 1-(2,6-dichlorophenyl)-3h-indol-2-one |
| 1-[2,6-bis(chloranyl)phenyl]-3h-indol-2-one |
| A809449 |
| NCGC00245217-01 |
| STK709153 |
| unii-cl5y02756k |
| cl5y02756k , |
| dtxcid4026979 |
| cas-15362-40-0 |
| NCGC00256032-01 |
| dtxsid6046979 , |
| tox21_301756 |
| 1-(2,6-dichlorophenyl)-2-oxoindoline |
| diclofenac amide |
| 1-(2,6-dichlorophenyl)oxindole |
| D4260 |
| HMS2295G12 |
| n-(2,6-dichlorophenyl)-2-indolinone |
| F1236-0045 |
| FT-0627229 |
| AM20060811 |
| 2h-indol-2-one, 1-(2,6-dichlorophenyl)-1,3-dihydro- |
| diclofenac potassium impurity a [ep impurity] |
| diclofenac sodium impurity a [ep impurity] |
| 2-indolinone, 1-(2,6-dichlorophenyl)- |
| aceclofenac impurity i [ep impurity] |
| SCHEMBL2982634 |
| diclofenac artifact |
| 1-(2,6-dichlorophenyl)-1,3-dihydro-2h-indol-2-one # |
| aceclofenac impurity i, european pharmacopoeia (ep) reference standard |
| n-(2,6-dichlorophenyl)indolin-2-one |
| mfcd00451393 |
| 1-(2,6-dichlorophenyl)-2-indolinone, aldrichcpr |
| SR-01000457522-1 |
| sr-01000457522 |
| n-(2,6-dichlorophenyl)-2-indolinone, analytical standard |
| diclofenac impurity a, european pharmacopoeia (ep) reference standard |
| J-009036 |
| n-(2,6-dichlorophenyl)-2-indolinone, british pharmacopoeia (bp) reference standard |
| BCP24489 |
| AS-12117 |
| voltindole (aceclofenac ep impurity i, diclofenac ep impurity a, diclofenac amide) |
| CCG-272701 |
| Q27275517 |
| SB64040 |
| diclofenac impurity a |
| aceclofenac impurity i |
| SY030556 |
| CS-0144094 |
| 1-(2,6-dichlorophenyl)-2,3-dihydro-1h-indol-2-one |
| EN300-7364240 |
| Z57241954 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The aim of this work was to compare the pharmacokinetic profiles of diclofenac from DICCIC (7." | ( Pharmacokinetic profile of a new diclofenac prodrug without gastroulcerogenic effect. Baldan-Cimatti, HM; Candido, CD; Davanco, MG; de Campos, ML; Dos Santos, JL; Nogueira, MA; Padilha, EC; Peccinini, RG, 2012) | 0.38 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 60.1180 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| TDP1 protein | Homo sapiens (human) | Potency | 23.1093 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 3.0638 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 39.8840 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 54.4827 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 29.5273 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 8.6349 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 43.6412 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 8.7076 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 45.7317 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 9.6885 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 49.5462 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 54.9410 | 0.0010 | 24.5048 | 61.6448 | AID743212 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 61.6448 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 1.7374 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 19.9526 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 61.5361 | 0.0016 | 28.0151 | 77.1139 | AID1259385; AID1259395 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 31.1006 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 61.1306 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 45.9174 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 61.1306 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 19.3312 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 61.1306 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID374370 | Cytotoxicity against human SW620 cells after 3 days by MTT assay | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis of 1-(2,6-dichlorophenyl)-3-methylene-1,3-dihydro-indol-2-one derivatives and in vitro anticancer evaluation against SW620 colon cancer cell line. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.91) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||